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Abstract
Multivalency achieves strong, yet reversible binding by the simultaneous formation of mul-
tiple weak bonds. It is a key interaction principle in biology and promising for the synthesis
of high-affinity inhibitors of pathogens. We present a molecular model for the binding affinity
of synthetic multivalent ligands onto multivalent receptors consisting of n receptor units ar-
ranged on a regular polygon. Ligands consist of a geometrically matching rigid polygonal core
to which monovalent ligand units are attached via flexible linker polymers, closely mimicking
existing experimental designs. The calculated binding affinities quantitatively agree with ex-
perimental studies for cholera toxin (n = 5) and anthrax receptor (n = 7) and allow to predict
optimal core size and optimal linker length. Maximal binding affinity is achieved for a core
that matches the receptor size and for linkers that have an equilibrium end-to-end distance
that is slightly longer than the geometric separation between ligand core and receptor sites.
Linkers that are longer than optimal are much preferable compared to shorter linkers. The
angular steric restriction between ligand unit and linker polymer is shown to be a key param-
eter. We construct an enhancement diagram that quantifies the multivalent binding affinity
compared to monovalent ligands. We conclude that multivalent ligands against influenza viral
hemagglutinin (n = 3), cholera toxin (n = 5) and anthrax receptor (n = 7) can outperform
monovalent ligands only for a monovalent ligand affinity that exceeds a core-size dependent
threshold value. Thus multivalent drug design needs to balance core size, linker length as well
as monovalent ligand unit affinity.
KEYWORDS: multivalency, binding affinity, pathogen inhibition, statistical mechanics mod-
eling
Multivalent interactions appear in a wide range of biological processes, including cell signaling,1,2
protein recognition,3–5 and cell adhesion.6,7 Multivalency describes the simultaneous binding be-
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tween several monovalent ligand and receptor units.3,8 Nature employs multivalency to enhance the
binding affinity of weakly binding moieties, such as lectins, which are proteins that interact with
carbohydrates.9,10 The potential of multivalency is best illustrated by considering the dissociation
constant of a specific lectin-carbohydrate pair, such as hemagglutinin and sialic acid. Hemagglu-
tinin, a trimeric lectin on the influenza virus surface, mediates the contact between virus and host
cell by binding to sialic acid, a sugar moiety covering epithelial cells.11 Each influenza virus carries
up to 1000 hemagglutinin proteins. Sialic acid ligands are expressed with a surface density of 0.5-
2 per nm2 on the host cell.12 The dissociation constant for monomeric hemagglutinin and sialic
acid is around K1=2.5mM,
13 which is a typical value for lectines.14 In contrast, the dissociation
constant between the entire virus and a host cell is estimated to lie in the pM range.12 Thus the
binding affinity, the inverse of the dissociation constant, increases by nine orders of magnitude,
which strikingly illustrates the potency of multivalent interactions. Furthermore, it has been shown
that a slight variation of the monovalent dissociation constant K1 between hemagglutinin and a
ligand molecule leads to an order of magnitude improvement of the multivalent binding affinity,
which is employed by nature to achieve strain selective binding.11,15 In fact, the binding enhance-
ment of multivalent ligands has been theoretically and experimentally shown to superselectively
depend on the receptor surface concentration.16,17 In efforts to utilize similar principles for the syn-
thesis of drugs against pathogens, in recent years multivalent ligand synthesis has moved into the
focus of attention.8,18,19 Pharmacological studies on low-molecular-weight vaccines and inhibitors
with tailored valency, size and molecular flexibility have been conducted.10,20 Typical synthetic
multivalent ligands consist of rigid cores of different chemical composition to which ligand units are
attached via flexible polymeric linkers.3,18,21,22 Multiple structural parameters, such as size and
shape of the core, as well as the linker length, together with costly and time-consuming synthesis













Figure 1: Multivalent ligand-receptor complexes: a) Structures of the multivalent receptors
considered in this paper: Hemagglutinin (n = 3, pdb-entry: 1hgg), Cholera toxin (n = 5, pdb-
entry: 1lta), Anthrax (n = 7, pdb-entry: 1tzo). The protein structure is shown in blue, the receptor
binding pockets are visualized by orange spheres. b) Our model for a trivalent ligand consists of
three ligand units which are attached to a rigid core via flexible, polymeric linkers.
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In Fig. 1a three prominent pathogen examples are shown: trivalent hemagglutinin, pentavalent
cholera toxin and the heptavalent anthrax receptor. As mentioned above, hemagglutinin plays
a crucial role in influenza infections. Influenza causes up to 500 000 deaths every year,23 which
illustrates the need for efficient anti-influenza drugs. So far, no drug targets the sialic acid bind-
ing receptor,24 one reason being the above-mentioned large monovalent dissociation constant of
K1=2.5mM.
12 Here, multivalent ligands hold high potential to improve the binding affinity.17,25,26
An even greater health risk is posed by cholera and anthrax, which involve the attachment of the
pentavalent cholera toxin and the heptavalent anthrax receptor to cells, respectively. Zhang et
al.27,28 and Joshi et al.29 have developed geometrically matching ligands which will be discussed
in detail further below. In both studies monovalent ligand units were attached to rigid cores via
flexible polymeric linkers. Joshi et al. investigated the influence of linker length on the dissociation
constant of a heptavalent ligand against the anthrax receptor for a single core size (results for the
dissociation constant are shown as symbols in Fig.4a), while Zhang et al. varied core size as well
as linker length of a pentavalent ligand against the cholera toxin (results are shown as symbols in
Fig.4b).
In the present paper we derive an analytically tractable theoretical model for the binding affinity
between multivalent ligand-receptor pairs. Our main aim is to derive explicit guidelines for the
rational ligand design in terms of structural ligand parameters. Our focus is on receptors with
binding pockets arranged on a regular polygon, as found for a wide range of biologically relevant
receptors. We restrict the model to ligands that have the same valency as the receptor, which is the
typical experimental situation. In previous works we and others investigated the impact of linker
flexibility on the binding affinity of divalent ligands.30–32 Here we extend these models to ligands of
higher valencies which adds considerable complexity to the theory. Our model results, presented by
lines in Fig.4 a and b, successfully reproduce both experiments. Beyond this validation, we study
the binding affinity for varying core size and find that the strongest binding is achieved for a core
size dcore that matches the receptor size drec. We also investigate the robustness of the binding
affinity with respect to variations of the linker length and find that ligand constructs with an
optimal core size require a precise choice of the linker length: linkers that are longer than optimal
are much preferable compared to linkers that are shorter than optimal. Our model identifies
the angular steric restriction between ligand units and linker chains as an important parameter
that significantly influences the multivalent binding affinity. Finally, we establish an enhancement
diagram based on parameter combinations for which a multivalent ligand binds more efficiently –
compared with the monovalent ligand unit – onto a multivalent receptor. The monovalent ligand-
receptor dissociation constant K1 here plays a key role: for given ligand core size and linker length,
a multivalent ligand can only beat the monovalent ligand if K1 is smaller than a critical value,




Figure 2: Multivalent binding modes: a) A trivalent ligand-receptor pair exhibits three
binding modes with one, two or three ligand units (red spheres) bound to the receptor pockets. b)
A pentavalent ligand with two bound ligand units exhibits two different binding patterns.
Results and Discussion
Multivalent Binding Affinity: The geometric parameters that characterize a multivalent ligand
receptor pair are visualized in Fig. 1b for the example of a trivalent receptor that interacts with
the corresponding ligand. The monovalent ligand units (red half spheres) are attached to the core
(green triangle) via flexible polymeric linkers that in experiments consist of polyethylene glycol
(PEG) or peptides.25,33 The linker length is parameterized by the unperturbed average end-to-
end distance rete. The distance from the ligand core midpoint to the corner is denoted as dcore.
Similarly, the distance between the receptor midpoint and the corner is denoted as drec. The
binding between n-valent ligands L and receptors R is described by the chemical reaction
L+R
 LR. (1)





where [L] is the concentration of free n-valent ligands, [R] is the concentration of free n-valent
receptors, and [LR] is the concentration of bound receptor-ligand pairs. The experimental key
quantity of interest is the half-maximal inhibitory concentration IC50, which is typically defined
as the total ligand unit concentration at which half of all receptors are bound to a ligand, so that
[R] = [LR] and thus Kn = [L]50. In the limit of dilute receptors we have [L]tot = [L] + [LR] ≈ [L]
and so IC50 = n[L]50 = nKn. We thus see that the dissociation constant Kn serves as an inverse
measure of the inhibitory efficiency of a ligand. Obviously, the main aim of multivalent ligand
design is to minimize the dissociation constant Kn. The definition of a bound ligand-receptor
complex deserves some discussion, since an n-valent ligand can bind onto an n-valent receptor in
n distinct modes that are distinguished by the number of bound ligand-receptor units, as shown
for a trivalent ligand in Fig.2a. In addition, for ligands with valency n > 3 there are different
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binding patterns for a given number of bound ligand units that have to be accounted for, as
shown in Fig.2b for a pentavalent ligand with two bound ligand units. One choice is to define a
ligand to be bound to a receptor when at least one ligand unit is attached to a receptor. This
choice is suitable for competitive inhibition assays where the host-pathogen binding is probed and
presumably also relevant in vivo.12,34 As shown in the Supporting Information (Fig. S5), for the
systems investigated here, the dominant contribution to the multivalent binding affinity comes
from the binding mode where all n ligand units are bound; taking also partially bound ligands
into account alters the dissociation constant by not more than a factor of two. Since the aim of
multivalent ligand design is to decrease the dissociation constant by several orders of magnitude,
we consider this deviation negligible. Accordingly, we define a ligand-receptor pair to be bound







A detailed derivation of Eq. 3 is given in the Supporting Information. We distinguish four contri-
butions: (1) The dissociation constant of the monovalent ligand unit K1. (2) The angular steric
restriction between ligand unit and linker chain ωLU (which will be explained below). (3) The
number of binding pockets per receptor subunit m, which is m=1 for hemagglutinin and cholera
toxin and m=2 for the anthrax receptor, as depicted in Fig.1a. (4) The cooperativity factor Cn.
While the effects of K1, ωLU and m factorize and hence enter Eq. 3 with a power of n, all non-
factorizing effects are contained in Cn.
Cooperativity Factor: Cn describes the conditional probability that if a single ligand unit is
bound to a receptor unit, the other n− 1 ligand units are located in receptor pockets as well. Ac-
cordingly, it has units of concentration to the power n-1 and generalizes the concept of an effective
concentration introduced for divalent ligands.35 It follows from the integral over the position and
angular orientation of the ligand core and the conformational integrals over all linker chains, while
taking into account that the linker chains cannot penetrate into the receptor surface. In our model,
we approximate the linker polymer distribution as Gaussian and neglect steric repulsion among
linker chains and between linker chains and the ligand core. The detailed calculation together with
a closed-form approximation for Cn is presented in the Supporting Information.
Angular restriction factor ωLU : We first discuss the impact of ligand angular restrictions for
a monovalent ligand unit. The monovalent dissociation constant K1 is proportional to an angular





where 8pi2 is the angular space of an unconstrained rigid body, which is the product of the ori-
entational space of a vector (corresponding to the area of a unit sphere 4pi) times a factor 2pi for
rotations around the body axis. The angular space available to a ligand that is bound within a





Figure 3: Angular restriction factor: a) Schematic picture (drawn to scale) of the ligand
unit that in the experimental study binds to the anthrax receptor, consisting of a helical peptide
connected to a PEG linker with N=15 monomers.29 b) Visualization of the angular restriction of
the ligand relative to the linker chain (left) compared to the free ligand (right).
0 < Ωbp < 8pi
2, which can give a sizable contribution to K1. If the ligand unit is bound to a linker
chain, the available angular space of the ligand unit ΩLU relative to the orientation of the linker
chain, which is approximately given by the linker end-to-end vector, will be reduced due to steric
effects. We illustrate this angular steric repulsion in Fig. 3 where we draw the alpha-helical peptide
ligand unit with amino-acid sequence HTSTYWWLDGAP, which has a length of roughly 1.5nm,
connected to a PEG linker with N=15 monomers, which is the ligand-linker construct actually
used to block the anthrax receptor.29 The PEG structure is a typical conformation from an MD
simulation36 and linker and ligand are drawn to scale. If we assume the linker chain in the bound
complex to be oriented perpendicularly to the receptor surface, the reduction of angular space due
to binding of the ligand unit into the binding pocket is not 8pi2/Ωbp, as for a monovalent ligand,
but rather ΩLU/Ωbp. Hence, we have to correct the monovalent binding constant K1 by a factor
ωLU = ΩLU/8pi
2 per bound ligand unit, which leads to the factor ωnLU in Eq. 3. In other words, the
more the orientation of the ligand unit is restricted, i.e. the smaller ωLU, the more the multivalent
dissociation constant Kn is reduced. In the comparison with experimental data, ωLU is the only
fitting parameter. We note that due to the fitting to experimental data, ωLU will also account for
other effects that modify the monovalent binding affinity and that are not accounted for in our
model, such as linker adsorption onto the receptor surface. A detailed discussion of the relation
between our model assumptions and the resulting fit value for ωLU is given in the Supporting
Information.
Linker-Length Influence: Joshi et al. synthesized a heptavalent ligand (schematically shown
in Fig.4c) based on seven alpha-helical peptide ligand units (shown in Fig.3a), which binds to the
anthrax receptor.29 The ligand core consists of cyclodextrin (Fig.4c). The PEG linker length is
varied between N=2 to N=27 monomers. By mutation studies of the receptor each of the seven
receptor subunits was found to exhibit two binding pockets29 as indicated in Fig.1a. The anthrax
receptors were pre-incubated with the lethal factor and the heptavalent ligands and afterwards
the cytotoxicity towards RAW264.7 cells was measured. In the experiment, the ligand unit con-
centration IC50 required to inhibit cytotoxicity by 50% was determined, in Fig.4a we show the
multivalent dissociation constant K7 = IC50/7 as open spheres in dependence of the linker length
rete. For ligands with short linkers rete ≤1.05nm the cytotoxicity inhibition was not measurable
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for ligand unit concentrations of up to 10−5M, which is indicated by crosses. We calculate rete
from the ideal scaling expression
rete =
√
b · a0 ·
√
N − 1 (5)
where the Kuhn length b=0.68nm and the monomer length a0=0.356nm for PEG have been de-
termined previously in MD simulations.36 The same simulations have also shown that the scaling
law in Eq. 5 holds even for short (N ≤24) polymers.
The theoretical dissociation constant K7 based on Eq. 3 is shown as a solid line in Fig.4a. For
the monovalent ligand dissociation constant we use a value of K1=2mM, which is reported as a
lower limit.29 The distance from the binding pocket to the receptor midpoint is determined from
the anthrax receptor crystal structure (pdb-entry: 1tzo) as drec=3.5nm for both binding pockets,
the core size of dcore=1.5nm is determined from the chemical structure of the ligand core shown
in Fig.4c. The only free parameter in Eq.3 is the angular restriction factor which by a fit to the
experimental data is given by ωLU = 0.06. The importance of ωLU becomes apparent by the plot
of K7 for the value ωLU = 1 (dashed line in Fig.4a), which corresponds to the scenario where
the ligand unit orientation is not influenced by the PEG linker: The dissociation constant K7 is
increased by more than seven orders of magnitude, since ωLU enters Eq.3 as the seventh power.
We note that changing the angular restriction factor ωLU shifts the dissociation constant in Fig.4a
vertically, while the position of the minimum, i.e. the optimal linker length, and the functional
dependence of the dissociation constant on the linker length are not altered. Hence, the optimal
linker length, which agrees nicely with the experimental value, is predicted in a parameter-free
fashion by our model.
Zhang et al.27,28 designed pentavalent ligands with four different core sizes that bind to the
cholera toxin B pentamer, which recognizes the GM1 ganglioside on the cell surface. The ligand
and receptor structures are schematically shown in Fig.4d. Galactose ligand units (indicated in
red in Fig.4e and f) are attached to a pentavalent core (indicated in green in Fig.4e and f) via a
polymeric linker, which is a heteropolymer of predominantly PEG units, as depicted in Fig.4e and
f. To estimate the average linker end-to-end distance rete, we divide the number of backbone atoms
by three to obtain an effective number of PEG monomers N . The average end-to-end distance
rete is then calculated by Eq.5. From the crystal structure (pdb-entry: 1ilta) the receptor size is
determined as drec=2.5nm. Experimentally a dissociation constant K1=100mM was determined
for monovalent galactose.27 Attaching a short linker (N=1 in Fig.4f) to the monovalent galactose
reduced the dissociation constant to K1=5mM,
37 which suggests additional attractive interactions
between the linker and the receptor, presumably due to the polar carbonyl group close to the
galactose unit. Since the anchoring chemistry between galactose and the linker is the same for
all pentavalent ligands, we use K1=5mM for our calculations. The IC50 values are obtained from
the attachment inhibition of cholera toxin to planar galactose-functionalized surfaces in an ELISA
assay, from which the dissociation constant follows as K5 = IC50/5.
7








































































































Figure 4: Multivalent ligand-receptor complexes: a) Dissociation constant K7 of a hep-
tavalent ligand that inhibits the anthrax receptor. Experimental data (spheres) from Ref.29 are
compared to Eq.3 (solid line) with a fitted angular restriction factor of ωLU = 0.06 (solid line)
and ωLU = 1 (broken line). For linkers shorter than rete ≤1.05nm the cytotoxicity inhibition was
not measurable, the upper experimentally measurable limit is denoted by crosses. b) Experimen-
tal dissociation constant K5 of pentavalent ligands with two different core sizes, which bind to
cholera toxin. The simultaneous fit of Eq.3 with n=5 (lines) to the two experimental data sets27,28
(data points) leads to ωLU = 0.03 (red dotted and blue broken lines). c) Chemical structure of
the experimentally used heptavalent ligand core.29 d) Schematic picture of the pentavalent ligand
and receptor. e) Chemical structure of the pentavalent ligand with a core size of dcore = 0.3nm.
The corresponding theoretically predicted dissociation constant is shown as a red dotted line in
subfigure b. f) Chemical structure of the pentavalent ligand with a core size of dcore = 0.8nm.
The corresponding theoretically predicted dissociation constant is shown as a blue dashed line in
subfigure b.
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In Fig.4b we compare experimental data for the smallest core size dcore=0.3 nm, consisting of
acylated pentacyclen (shown in Fig.4e) and the largest core size dcore=0.8 nm, consisting of a
cyclic peptide structure (shown in Fig.4f) with our model (dashed blue and red dotted lines).
The angular restriction factor ωLU = 0.03 results from a simultaneous fit to both experimental
data sets, the agreement with the experimental data is convincing. Not surprisingly, the optimal
linker length (corresponding to a minimal value of K5) is larger for the smaller core size. We also
present the theoretical prediction for an even larger ligand core with dcore=1.2nm (black solid line
in Fig.4b) for the same value ωLU = 0.03. The minimal dissociation constant K5 is further reduced
by an order of magnitude. We observe that the curvature of K5 around the minima increases with
increasing dcore, meaning that the robustness of the binding affinity with respect to variations of
the linker length away from the optimal value decreases as the ligand core size is optimized; we
will come back to this point later on. The dissociation constant K5 as a function of dcore for fixed
linker length is presented in the Supporting Information Fig. S7.
Core Size Influence: Fig.5a shows K5 in dependence of the ligand core size dcore for the same
parameters and in particular using the same fitted value for the angular restriction factor ωLU as
in Fig.4b for cholera toxin. As discussed before, changing the value of ωLU shifts the dissociation
constant by a constant factor, while the optimal linker length and core size remain unaltered. We
present model predictions for the optimal linker length roptete that minimizes K5 (solid line) as well as
for a linker that is shorter rete = r
opt
ete−0.3nm (dotted line) and longer rete = roptete +0.3nm (dashed
line) than optimal. Not surprisingly, we see that the ligand is most efficient, which means K5 is
smallest, if the ligand core size is similar to the receptor size (dcore = drec is denoted by a vertical
broken line). In Fig.5b the optimal linker length roptete is shown in dependence of dcore as a solid
line. roptete is slightly larger than the difference between receptor size and core size |dcore − drec|,
denoted by broken straight lines. The right axis denotes the number of PEG monomers N , since a
linker polymer consists of a discrete number of monomers, the experimental linker length can never
exactly match the optimal value. As can be seen in Fig.5a, a linker that is shorter than optimal
leads to a significantly increased K5, in particular for close-to-optimal values of dcore, a linker that
is slightly longer than optimal only increases K5 slightly. We conclude that in experimental ligand
design, the linker should preferably be slightly longer than optimal, not shorter. Fig.5a also shows
the experimental optimal dissociation constants K5 for core sizes dcore = 0.3nm, 0.5 nm, 0.7 nm
and 0.8 nm that correspond to the minimal values of K5 with respect to linker length.
27,28 In
agreement with the model predictions, K5 remains nearly constant for core sizes smaller than 1nm
and the drastic improvement of binding affinity for increasing core size was not reached in the
experiments.
Multivalent Enhancement Diagram: The black horizontal line in Fig.5a denotes K5 = K1/5 =
1 mM, for which the IC50 value of the pentavalent ligand is the same as of the monovalent ligand.




Figure 5: Influence of ligand core size dcore: a) Dissociation constant K5 of a pentavalent ligand
binding to cholera toxin as a function of dcore, optimal size match between ligand and receptor
dcore = drec = 2.5nm is indicated by a vertical dashed line. Schematic pictures are shown at the
top. Results for optimal linker length (solid line) are compared with linkers shorter (dotted line)
and longer than optimal (broken line). Experimental results for K5 for optimal linker length are
shown as colored symbols. The IC50 value of the monovalent ligand, K1/5=1mM, is shown as a
horizontal solid line. b) Optimal linker length roptete (solid line). The difference between core size
and receptor size, |dcore − drec|, is denoted by straight dashed lines.
a core size larger than dcore =4.6nm, the monovalent ligand binds more efficiently to the cholera
receptor than the multivalent ligand, even when its linker length is optimized. This means that the
monovalent dissociation constant K1 is a crucial parameter which determines whether a multivalent
ligand with a certain core size can be more efficient than its monovalent counterpart.
More generally, a multivalent ligand produces an α-fold binding enhancement compared to the
monovalent ligand if the multivalent and monovalent dissociation constants satisfy the condition












In Fig.6a we show Eq.6 in dependence of the ligand-receptor size ratio dcore/drec for enhancement
factors of α = 1, 103, 106, 109 and for optimized linker length rete = r
opt
ete . We present results for
trivalent ligands binding to the hemagglutinin receptor (n = 3, left panel), pentavalent ligands















































Figure 6: Multivalent enhancement diagram: a) Monovalent dissociation constant K1 from
Eq.6 required to reach multivalent enhancement factors α = 1, 103, 106, 109 as a function of the
ligand-receptor size ratio dcore/drec for optimal linker length r
opt
ete for trivalent (n = 3, left), pen-
tavalent (n = 5, middle) and heptavalent (n = 7, right) receptor-ligand pairs. The experimental
monovalent dissociation constants K1 = 2.5mM (n = 3), K1 = 5mM (n = 5) and K1 = 2mM
(n = 7) are shown as a horizontal broken lines. The angular restriction factor is set to ωLU=0.06
(n=3), ωLU=0.03 (n=5), ωLU=0.06 (n=7). In accordance with the receptor structure in Fig.1a
the number of binding pockets per receptor subunit m and the receptor size drec is set to m=1,
drec=2.6nm (n=3), m=1, drec=2.5nm (n=5) and m=2, drec=3.5nm (n=7). b) Rescaled optimal
linker length roptete /|dcore−drec|, the geometric limit roptete = |dcore−drec|) is denoted by dashed lines.
to the anthrax receptor (n = 7, right panel). The plots in Fig. 6a constitute enhancement
diagrams of multivalent ligands, for a desired enhancement factor α and given ligand-receptor
size ratio dcore/drec the lines allow to determine the required monovalent dissociation constant
K1. The estimated values of the experimental monovalent dissociation constants K1 = 2.5mM
(hemagglutinin13), K1 = 5mM (cholera toxin
27,28) and K1 = 2mM (anthrax
29) are indicated by
broken horizontal lines. For values of the monovalent dissociation constant K1 above the solid line,
which indicates the case α = 1, a multivalent ligand is less efficient than its monovalent counterpart.
For penta- and heptavalent ligands, we see that in order to reach an α = 106-fold multivalent
enhancement (broken line), the ligand core size must be in the range 2.1nm < dcore < 4.9nm
(for n=5) or 1.7nm < dcore < 3.4nm ( for n=7), respectively. To reach the same enhancement
for hemagglutinin with sialic acid as a ligand unit, the core size must almost exactly match the
optimal value dcore = drec, which would be very difficult to achieve in practice. If the linker length
is off its optimal value, the restrictions on the core size are even more stringent (see Supporting
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Information). The rescaled optimized linker length, roptete /|dcore − drec|, is shown as a function
of dcore/drec in Fig. 6b. In agreement with our results for the optimal linker length r
opt
ete of a
pentavalent ligand shown in Fig.5b, we find that roptete is always slightly larger than the difference
between core size and receptor size |dcore − drec|. The multivalent enhancement diagrams in Fig.
6a put very stringent constraints on the geometric design of multivalent ligands with a desired
performance as quantified by the enhancement factor α. The monovalent dissociation constant K1
turns out to be the limiting factor.
Conclusion
We present an analytic model for the binding affinity between multivalent ligand-receptor pairs
that accounts for fluctuations of ligand core position and ligand core orientation as well as for
conformational fluctuations of the polymeric linkers. Comparison with experimental multivalent
binding data for pentavalent cholera ligands and heptavalent anthrax ligands is satisfactory and
identifies the angular restriction between ligand units and linker polymers, quantified by the factor
ωLU, as a key ingredient of multivalent enhancement, which we believe is relevant also for multi-
valent binding in soft supramolecular structures, artificial self-assembling systems or self healing
systems.38–41 Our findings show that the highest gain in binding affinity is achieved for a ligand
core size that matches the receptor size. In turn, a mismatch between core size and receptor size
leads to a strong decrease of the binding affinity even for optimized linker length, this would allow
multivalent ligands to discriminate between receptors of different size. The optimal linker length
is slightly longer than needed to span the distance between receptor and core. The monovalent
dissociation constant K1 significantly influences the enhancement factor of an optimally designed
multivalent ligand. We conclude that for the development of high affinity multivalent inhibitors
against multivalent pathogens3,42,43 the multivalent ligand geometry and the monovalent ligand
unit binding affinity have to be balanced.
In our model we consider the valency of the ligands to precisely match the valency of the recep-
tors, which is the prevalent scenario that is considered experimentally. Note however that Kitov et
al.21 designed a decavalent cholera toxin inhibitor. In future work it would therefore be interesting
to generalize our model and to treat also the case of non-matching ligand and receptor valencies.
We considered the idealized case where one multivalent ligand interacts with only one multivalent
receptor, which corresponds to the limit of large spatial separation between neighboring multi-
valent receptors. For densely packed receptors a single multivalent ligand could bridge between
different multivalent receptors, which would increase the number of binding patterns and therefore
further strengthen the binding. For the meaningful modeling of such more complicated situations
one would of course need to know the separation distribution between multivalent receptors.
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